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Abstract
Cancer Research UK and Ludwig Cancer Research convened an inaugural international Cancer Prevention and
Nutrition Conference in London on December 3–4, 2018. Much of the discussion focused on the need for systematic,
interdisciplinary approaches to better understand the relationships of nutrition, exercise, obesity and metabolic
dysfunction with cancer development. Scientists at the meeting underscored the importance of studying the temporal
natural history of exposures that may cumulatively impact cancer risk later in life.
A robust dialogue identified obesity as a major risk for cancer, and the food environment, especially high energy and
low nutrient processed foods, as strong and prevalent risk factors for obesity. Further engagement highlighted
challenges in the post-diagnostic setting, where similar opportunities to understand the complex interplay of nutrition,
physical activity, and weight will inform better health outcomes.
Going forward, holistic research approaches, encompassing insights from multiple disciplines and perspectives, will
catalyze progress urgently needed to prevent cancer and improve public health.
Keywords: Cancer prevention, Diet, Nutrition, Physical activity, Obesity, Metabolism, Interdisciplinary, Epidemiology,
Epigenetics, Developmental origins, Public health
Introduction
Robert L. Strausberg (Fig. 1) and Fiona Reddington (Fig. 2)
Over the past half century, much progress has been
made in improving treatments for patients with cancer.
Yet, the mortality rate from cancer remains unacceptably
high. Alleviating the mortality, morbidity, and impact on
quality of life attributable to cancer is a global health pri-
ority of increasing relevance to countries across the eco-
nomic spectrum.
Recent data suggest that approximately four in ten
cancers are preventable through behavior changes alone
[1, 2]. Public health measures have made progress in this
area; these include prevention of lung cancer, which is
largely addressed through smoking cessation, malignant
melanoma, by limiting exposure to UV light, and cer-
vical cancer by immunization against human papilloma-
virus. However, in the important area of diet, nutrition,
and cancer prevention there is still much to learn about
how to catalyze effective prevention efforts globally (see
the EPIC study http://epic.iarc.fr/).
Having a shared goal of taking a radically new ap-
proach to cancer prevention, Ludwig Cancer Research
and Cancer Research UK have sought to highlight the
challenges and opportunities to enhance progress in this
important area of public health research. A goal is to
make this field a ‘go to’ area for the best and brightest
scientists to perform research that will make for health-
ier people throughout the world.
In this spirit, Cancer Research UK and Ludwig Cancer
Research convened an inaugural international Cancer Pre-
vention and Nutrition Conference at the Francis Crick In-
stitute in London on December 3–4, 2018. Discussions at
the conference considered the field holistically, weaving
together insights from multiple disciplines and perspec-
tives. The sessions were organized into six distinct areas,
which are important individually, but even more powerful
when integrated. In this Forum article, the session chairs
of the meeting have served as co-authors and prepared
their sections in conjunction with the other speakers.
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The meeting included much discussion about the chal-
lenges in defining effective prevention strategies based
on nutritional and dietary change. Interdisciplinary re-
search, incorporating disciplines such as business and
marketing, political science, environmental sciences,
geography, data and systems sciences, as well as simula-
tion modeling, offers great promise.
Participants at the conference were encouraged to con-
sider multiple risk factors within the context of cancer
prevention. As the world continues to open – with im-
proved mechanisms to share data, enhanced collaboration
across continents, and cross-pollination increasing among
traditional siloes – the links between nutrition and cancer
prevention research are potentially more understandable
and actionable. This provides an outstanding opportunity
to invigorate conversations and stimulate the broadest
spectrum of research talent to work in concert.
We hope that this Forum article will stimulate new ap-
proaches to cancer prevention research that are scientific-
ally, methodologically, technologically, and internationally
integrated and conducted with a clear sense of urgency to
improve public health.
Understanding dietary risks and cancer
Walter C. Willett (Fig. 3) and Elio Riboli (Fig. 4)
Methodological issues
Interest in diet in the cause and prevention of human
cancers was fueled in the 1970s and ‘80s by findings
from ecological studies documenting large international
differences in cancer rates that were correlated with per
capita intakes of meat, fat, and other dietary factors [3].
In migrant studies, populations moving from low- to
high-incidence regions developed cancer rates like those
of long-term residents, indicating that these major differ-
ences were not due to population genetic factors. The
effects of various dietary factors on tumorigenesis in ani-
mal models heightened attention to diet, but more de-
tailed human studies were needed because the ecological
correlations were potentially confounded by many non-
dietary variables. Since 1980, much attention has been
devoted to methodological issues in the study of diet
and human cancer, including study design, assessment of
diet, and analysis of epidemiologic data on diet [4]. Most
of the early studies of diet and cancer used case-control
designs in which diet was assessed retrospectively after
the diagnosis of cancer. Concerns about biases due to se-
lection of participants and recall of diet have been proven
to be justified because later results of prospective studies
often did not support the earlier findings. Thus, prospect-
ive cohort studies, in which diet is assessed before the out-
comes are known, have become the primary design.
Early analyses of day-to-day variation in dietary factors
indicated that in order to measure the intake of an individ-
ual of most nutrients and foods, recall of consumption over
Fig. 1 Robert Strausberg, PhD, is Deputy Scientific Director for the
Ludwig Institute for Cancer Research. His scientific focus is on
interdisciplinary approaches to improve the health of people
worldwide through disease prevention and early intervention.
Previously, he was Deputy Director of the J. Craig Venter Institute
and served in leadership positions at the National Human Genome
Research Institute, the National Cancer Institute, and the Institute
for Genomic Research
Fig. 2 Fiona Reddington is Head of Population, Prevention and
Behavioural Research Funding at Cancer Research UK and oversees
the research portfolio in the areas of population research, prevention
and early diagnosis. Following her BSc in Pharmacology and PhD in
Neurophysiology, she went on to join the NHS as a project manager
and subsequently moved into management roles at a national cancer
network and the NCRI Informatics Initiative
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a 24-h period would be required. [5]. Thus, various forms
of food frequency questionnaires (FFQs) have become the
most widely used method of dietary assessment in epi-
demiological studies. Whether FFQs have enough validity
to detect important associations has been addressed in
many studies using both biomarkers and detailed recording
of diets as comparators [6]. These studies have documented
adequate validity, particularly for energy-adjusted intakes,
which are of primary interest because changes in nutrient
and food intake must be made within narrowly constrained
energy intakes. Validity is supported by robust and
replicated findings for many dietary factors measured by
FFQs as predictors of diabetes and cardiovascular disease.
Biomarkers of diet can complement assessments of intake,
but these also have limitations as they are not available
since many aspects of diet are rarely measured repeatedly
to capture long-term exposures and are usually influenced
by multiple nondietary factors.
Overview of the role of diet in cancer causation
Beginning in the early 1980s, the possibility that diet could
be a key link between what was generically called the ‘envir-
onment’ and cancer led to a new generation of very large
cohorts of healthy volunteers who provided data on diet
and other behavioral characteristics at baseline and were
followed for cancer incidence and mortality. The World
Cancer Research Fund started, in the mid-1990s, the first
worldwide effort to systematically review and summarize
the epidemiological evidence on diet and cancer, which ma-
terialized in the 1997 First World Cancer Research Fund
Report, followed by subsequent reports in 2007 and 2018.
Based on the aggregate of several thousand publications in
more than 50 large population cohorts and several million
study participants, diet during mid-life appears to have a ra-
ther weak association with subsequent cancer risk [7]. Even
when there is substantial consistency between studies in
different populations, as is the case for red meat and fiber-
rich foods and colorectal cancer, the variation in risks be-
tween high and low consumption levels are relatively mod-
est (e.g., risk ratio in the order of 1.2–1.5). However, the
prospective nature of the cohorts and the baseline an-
thropometric measurements taken in many cohorts, as well
as some assessment of physical activity, has provided con-
vincing, and initially unexpected, evidence that overweight/
obesity is associated with increased risk of many cancers
while moderate or high levels of physical activity are associ-
ated with reduced risk. Therefore, from a simple view that
particular foods consumed could be a major factor modu-
lating cancer risk between individuals and across the world,
two decades of research based on very large scale epidemio-
logical cohort studies have led to the current understanding
that it is in most instances the combination of the type of
food, the level of regular physical activity, and the accumu-
lation of body fat (or its distribution and/or the ratio be-
tween fat/lean tissue mass) that constituted the basic triad
of important metabolic factors that influence cancer
development.
The complexity of the metabolic factors modulated by
diet/anthropometry and physical activity may be a contrib-
uting factor for the lack of support for several prominent
food and cancer hypotheses in large prospective studies, ra-
ther than just inadequate dietary assessment. In addition, it
could be related to the natural history of cancer, in which
exposures may act early in life and decades before diagno-
sis. Until now, few studies have been able to examine these
Fig. 4 Elio Riboli holds an MD degree and an MPH from the
University of Milan and a MSc in Epidemiology from Harvard University.
In 1990, he initiated the European Prospective Investigation into Cancer
and Nutrition, a large population-based cohort designed to investigate
the role of diet, nutrition and metabolic factors in the etiology of cancer
and other chronic diseases. In 2006, he moved to Imperial College,
where he became the first Director of the Imperial School of Public
Health (2008–2017) and continues his research in the field of nutritional
epidemiology of cancer
Fig. 3 Walter Willett is Professor of Epidemiology and Nutrition at
the Harvard T.H. Chan School of Public Health and Professor of
Medicine at Harvard Medical School in Boston, Massachusetts. He
served as Chair of the Department of Nutrition at Harvard T.H. Chan
School of Public Health for 25 years. He has published over 2000
articles, primarily on lifestyle risk factors for heart disease and cancer,
and has written the textbook Nutritional Epidemiology
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temporal relationships; filling these gaps should be a prior-
ity for future research. While awaiting the development of
cohorts to address these gaps, much could be learned from
the systematic analysis of unexamined data on diet and can-
cer that already exists; support for such collaborative efforts
would be highly cost-effective.
Interfacing laboratory, epidemiological, and other
clinical studies – moving from links to cause
Richard M. Martin (Fig. 5) and Edward L. Giovannucci (Fig. 6)
Large geographic and temporal variations in cancer inci-
dence and survival point to important environmental deter-
minants, and epidemiological and laboratory studies indicate
a key role for dietary factors in cancer development and pro-
gression [8]. These considerations suggest substantial poten-
tial for the development of cancer prevention strategies.
However, the continuing debate around dietary interventions
and policies illustrates the challenges of generating robust
causal evidence for action. The current nutrition and cancer
evidence-base is largely observational and prone to con-
founding, reverse causality, and inaccurate exposure assess-
ment, precluding confident causal inference. Further, the
biological pathways underlying diet and cancer relationships
are poorly understood, pre-clinical data only weakly reprodu-
cible [9] and, while randomized controlled trials are the gold
standard, they are expensive, time consuming, often not feas-
ible, and can only address a limited number of interventions
in selected populations.
How do we move from observational associations to causal
links?
Recent advances in high-throughput assays to measure
the genome, methylome [10–14], metabolome [15, 16],
transcriptome [17], microbiome [18], and proteome [19],
together with the creation of large research consortia and
population biobanks, have vastly expanded the availability
of high-dimensional molecular datasets from human sam-
ples, many of which are accessible through a range of bio-
informatic platforms [20–22]. These studies have enriched
our understanding of gene regulation and function [23]
and provide an unparalleled resource for furthering our
understanding of the causal underpinnings of cancer.
For example, with the surge in genome-wide association
studies, Mendelian randomization has become firmly
established as a major analytical tool in the causal under-
standing of cancer risk and mechanisms – robust germ-
line genetic instruments from genome-wide association
studies can now proxy thousands of cancer-related modifi-
able exposures and metabolic traits, and genome-wide
data on tens- to hundreds-of-thousands of individual site-
specific cancers are readily available [21, 22, 24]. In the
field of epigenetics, we are now able to exploit recent ad-
vances in understanding the genetic architecture of DNA
Fig. 5 Richard Martin is a Professor of Clinical Epidemiology at the
University of Bristol and Honorary Consultant in Public Health. His
research interests include cancer epidemiology, the application of
causal analysis methods to strengthen the evidence for developing
primary and tertiary prevention interventions, and the identification
of -omic biomarkers for secondary prevention
Fig. 6 Edward Giovannucci graduated from Harvard University in
1980, received an MD from University of Pittsburgh in 1984, and
then completed a doctoral degree in epidemiology from the Harvard
T.H. Chan School of Public Health in 1992, where he is currently a
Professor in the Departments of Nutrition and Epidemiology. His
research focuses on how nutritional, environmental, and lifestyle factors
relate to various cancers
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methylation variation across the human life course [14] to
develop methods for investigating molecular mediation.
DNA methylation-based biomarkers that reflect risk fac-
tors (rather than disease processes themselves) may pro-
vide a useful strategy to refine risk estimates and provide
novel opportunities for risk-tailored screening and cancer
prevention [25–28]. Indeed, the use of systemic molecular
biomarkers, such as DNA methylation variation, may cap-
ture integrated biological effects of inter-related exposures
(such as diet, physical activity and adiposity, and their
downstream physiological consequences), and be more
strongly associated with and predictive of cancer than fo-
cusing on single nutrient factors [29].
Promising advances in molecular epidemiological stud-
ies, the willingness of groups to collaborate to create large-
scale consortia and the development of novel causal analyt-
ical methods, combined with our ability to readily integrate
epigenomics, transcriptomics, metabolomics, and proteo-
mics with data on hundreds of diseases, mean that we can
readily map the influence of these molecular traits on com-
plex human diseases, including cancer. In this way, we will
more efficiently and robustly be able to rapidly prioritize
potential interventions for independent replication or
follow-up in experimental studies, based on robust causal
analysis [30–32], deprioritize other targets, minimize
deploying resources on non-causal targets [33, 34], predict
unexpected effects (adverse and beneficial) of an interven-
tion [35], validate exploratory analyses from clinical trials
[36], and identify potential biological mechanisms under-
pinning exposure-cancer associations [30–32].
Evidence will continue to evolve with the complexity of
changing exposures and population characteristics. Thus, a
dynamic approach to measuring the entirety of the evi-
dence from different sources, assessing outcomes of
policies or natural experiments, and continuing surveil-
lance are still needed. Nevertheless, the improved
characterization of exposures, mechanisms, and biological
understanding at the population level can contribute to
strengthening confidence in preventive interventions.
Metabolic health – dietary, genetic, and
epigenetic factors
Marc J. Gunter (Fig. 7) and Hal Drakesmith (Fig. 8)
The reprogramming of energy metabolism, one of the
hallmarks of cancer and metabolic transformation, is a key
event in tumorigenesis. The importance of metabolic dys-
function in driving cancer is supported by both observa-
tional and experimental evidence. For example,
epidemiological studies have shown that obesity increases
the risk of developing at least 12 different types of cancer
[37], while data from both human studies and animal
models have demonstrated that mutations in cellular
pathways linking nutritional status and growth are fre-
quently mutated in cancer (e.g., mTOR, PI3K). Currently,
we do not fully understand the biology that connects
metabolic dysfunction with cancer development at either
a cellular or systemic level. However, accumulating evi-
dence from multiple arenas of research are beginning to
suggest some key links for how the overall metabolic state
of the individual may drive molecular mechanistic alter-
ations that underlie or accelerate carcinogenesis. Estab-
lished mechanisms include obesity-associated alterations
in systemic hormones and growth factors (particularly in-
sulin and insulin-like growth factor-1, leptin, and sex ster-
oid hormones), which induce pro-cancer signals in
preneoplastic or neoplastic cells through their respective
receptors [38–40]; cytokines and other inflammatory mol-
ecules are also altered and signal through their receptors
and downstream signaling pathways.
Mitochondria govern cellular energy metabolism, and
analyses of gene expression profiles of cancer patients
Fig. 7 Marc Gunter is Head of the Section of Nutrition and
Metabolism at the International Agency for Research on Cancer, the
specialized cancer research agency of the World Health Organization.
Dr. Gunter’s research focuses on the role of nutrition, diabetes, and
obesity in the natural history of cancer, with an emphasis on metabolic
dysfunction and in particular the insulin/IGF/mTOR pathway. He is
principal investigator of a number of studies applying high dimensional
metabolic profiling within the framework of large prospective and
clinical cohorts, as well as intervention studies to identify novel
biochemical pathways involved in cancer development and prognosis
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from The Cancer Genome Atlas revealed that mitochon-
drial genes are suppressed in cancers with poor clinical
outcomes [41]. Further, mutations in key metabolic en-
zymes in the mitochondria, such as fumarate hydratase,
succinate dehydrogenase, and isocitrate dehydrogenase,
can cause cancer. For example, cells lacking functional
fumarate hydratase accumulate fumarate, which in turn
activates a plethora of biological processes linked with
tumorigenesis [42].
Some cancer cells have increased uptake of certain non-
essential amino acids, such as serine and glycine, which
support maximal cancer cell proliferation [43]. Serine and
glycine contribute to the synthesis of nucleotides (both
DNA and RNA), proteins, and the antioxidant glutathione
[44]. While nonessential amino acids can be synthesized de
novo, diet is also an important source of these amino acids.
Together, these findings suggest that dysregulated me-
tabolism can work in parallel to canonical oncogenic
cascades to drive cancer, and that dietary input is a con-
tributing factor to supplying the needs of altered cancer
cell metabolism. In several models for cancer, dietary re-
striction of serine and glycine can slow tumor growth,
increase survival, and potentiate the activity of antican-
cer drugs [45]. Therefore, targeted dietary interventions
may be a viable way to enhance cancer therapy and im-
prove survival in some cancer patients.
An interesting link for how diet might influence cancer
development is through the interface of gut microbes, the
metabolites they produce, and the immune system.
Within the gut, the microbiota and the immune system
regulate intestinal function and interact with dietary com-
ponents to maintain tissue function. In particular, a popu-
lation of immune cells called regulatory T cells, arises in
the intestine and their differentiation is driven in part by
specific members of the commensal microbial community
and their metabolic products [46]. These cells in turn
regulate the composition and metabolic status of com-
mensal microbiota and maintain a fine balance between
immunity and tolerance in the gut, whilst also restraining
precancerous lesions in the gastrointestinal tract.
Overall, these studies demonstrate new links between al-
tered cellular metabolism, often driven by mitochondrial
dysfunction, interacting with specific dietary components
to produce an imbalance of metabolites within a cell that
can promote tumor growth. Systemic adiposity contrib-
utes to the development of some cancers, potentially
through gut-oriented processes that affect intestinal
microbiota and immune activity, which in turn influence
inflammation and energy balance. In terms of preventative
measures, a low body fat state is protective against certain
cancers. However, understanding how particular dietary
factors, biochemical processes, and metabolites interact
with microbial, immune, and other environmental factors
to generate cancer risk remains a considerable challenge.
Nevertheless, the rationale that dietary and metabolic in-
terventions have a role to play in preventing cancer is in-
creasingly supported from a firm mechanistic basis.
Developmental origins of cancer
Karin B. Michels (Fig. 9) and Robert A. Waterland (Fig. 10)
Environmental influences during critical developmental
periods can have a long-lasting impact on the risk of
many diseases, including cancer. The study of such long-
term effects of early exposures is broadly referred to as
the developmental origins of health and disease (DOHaD).
Animal and human population-based studies indicate that,
during prenatal and early postnatal life, exposures such as
through nutrition, radiation, infection, pharmacologic ex-
posures, and environmental contaminants can set the
stage for increased cancer susceptibility later in life.
Available evidence for the developmental origins of
cancer is strongest for some types of cancer. The best
studied cancers with respect to early life influences are
breast cancer, leukemia, and uterine cancer. For breast
cancer, high birthweight, high birth length [47, 48], early
age at peak growth [49] and early menarche [50] (all po-
tential indicators of early overnutrition and exposure to
growth factors), as well as early exposure to radiation
[51] and low body fatness in childhood [52] are all asso-
ciated with an increased risk of later breast cancer. Ma-
ternal pre-eclampsia [48] and caloric restriction during
adolescence and early adulthood [53] are associated with
Fig. 8 Hal Drakesmith was trained at the University of Cambridge,
University of Kyoto, and University College London before moving
to the University of Oxford. His laboratory in the MRC Human
Immunology Unit at the Weatherall Institute of Molecular Medicine
works on the interaction of iron homeostasis with immunity, metabolism,
anemia, and inflammation
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reduced risk of later breast cancer. High birthweight has
also been associated with elevated risk of several child-
hood and other adult cancers [54–56]. Other types of
cancer have been linked to more specific early expo-
sures, such as paternal pre-conceptional smoking to
childhood leukemia [57], childhood infections to Hodg-
kin’s and non-Hodgkin’s disease [58], infections during
pregnancy to leukemia [59], and factors affecting im-
mune development at birth to pediatric leukemias [60].
Intrauterine exposure to diethylstilbestrol has been
linked to increased risk of developing adenocarcinoma
of the vagina [61].
Clearly, if a considerable proportion of lifetime cancer
risk is determined by environmental factors during early
life, understanding cancer from a DOHaD perspective may
provide new opportunities for cancer prevention. Identify-
ing the windows of susceptibility during early life, narrow-
ing down the most important modifiable risk factors that
shape cancer predisposition, unravelling relevant mecha-
nisms, and understanding why some cancers are particu-
larly sensitive to early influences are essential steps to move
this agenda forward. Parsing the attributable fraction of
cancer type-specific risk factors, including diet, physical ac-
tivity, obesity, infection, radiation, and environmental che-
micals, at various points across the life course will enhance
our understanding of cancer etiology and inform preven-
tion strategies. Optimizing life choices, such as diet, may
need to take into consideration balancing the risk of other
conditions such as cardiovascular disease or diabetes.
Two major barriers to progress are (1) the long period
of time between the early exposure and the resulting
cancer – up to several decades – and (2) our limited un-
derstanding of the fundamental biological mechanisms
mediating these long-lasting effects [62]. Regarding the
first, in our view, initial efforts focused on understanding
the developmental origins of childhood cancer should be
a top priority; this would allow the design of studies
spanning several years rather than decades [63]. Further,
the pooling of existing cohort data with relevant expos-
ure data and available follow-up data for cancer should
be a key effort. To the extent that the developmental ori-
gins of childhood and adult cancer share mechanistic
features, knowledge gained from studies of childhood
cancer will help refine DOHaD studies of adult cancers.
Regarding the second barrier, there are emerging oppor-
tunities to advance our understanding of the role of epi-
genetic and other mechanisms in the developmental
origins of cancer. The diseases most commonly studied
with respect to DOHaD are hypertension, cardiovascular
disease, obesity, and type 2 diabetes; relatively few studies
Fig. 9 Karin B. Michels, ScD, PhD, is Professor and Chair of the
Department of Epidemiology at the UCLA School of Public Health in
Los Angeles, California. Her research interests include cancer, nutritional,
and epigenetic epidemiology. She has made seminal contributions to
elucidating the early life origins of cancer, specifically breast cancer
Fig. 10 Robert A. Waterland, PhD, is a Professor of Pediatrics and
Molecular and Human Genetics at Baylor College of Medicine in
Houston, Texas. His research focuses on understanding epigenetic
mechanisms in the developmental origins of health and disease
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have focused on DOHaD and cancer. This is surprising,
given that epigenetic mechanisms are currently the most
studied mechanisms postulated to explain the long-term
persistence of developmental programming [64] and can-
cer is, by far, the most studied (and best understood)
chronic disease with respect to epigenetic etiology. The
stage is set for rapid advances in epigenetic mechanisms
mediating the developmental origins of cancer if more re-
search can be stimulated in this area. A major hurdle fa-
cing such studies is the cell type-specificity of epigenetic
markers [64]; yet, recent studies have made progress iden-
tifying human metastable epialleles, which exhibit sys-
temic interindividual variation in DNA methylation [65],
and initial studies are showing promise using these as
markers of cancer risk [66].
Longitudinal data collection with real-time exposure
assessment, biospecimen collection, and endpoint ascer-
tainment remain challenging but are urgently needed.
Alternatively, retrospective studies exploiting docu-
mented or manifested exposures such as clinical records
and/or previously collected specimens (e.g., newborn
blood spots or Guthrie cards) can be useful. A novel re-
cent investigation using Guthrie cards suggested that
pregnancy levels of androgens were associated with tes-
ticular tumors that developed in adolescents but not
among infants [67]. Guthrie cards are additionally useful
for measuring immune development [68], nutrition [69],
and DNA methylation [70]. Rather than waiting for can-
cer to manifest, it may be feasible to identify intermedi-
ate endpoints that can be utilized as markers of future
cancer risk. Identification of such intermediate markers
will benefit from consideration of molecular and cellular
aspects of carcinogenesis. There are many opportunities
to apply mechanistic insights from animal model studies
to refine population-based analyses.
Prevention efforts may start prior to conception by tar-
geting gametes and preventing epigenetic errors, exploring
what represents an optimal pregnancy diet, and evaluating
neonatal screening for acquired genetic mutations and
congenital cytomegalovirus infection. Whether vaginal
birthing may affect cancer susceptibility via modulation of
the microbiome and the innate immune function remains
to be explored in both animal and population-based stud-
ies. It remains unresolved whether cancer screening and
active prevention is possible for cancers like leukemia.
Risk stratification based on genetic predisposition repre-
sents another sensible yet underexplored avenue for early
intervention to reduce future cancer risk.
Stored biological samples and existing clinical data sug-
gest outstanding opportunities for multidisciplinary teams
to test associations, understand underlying mechanisms,
and design interventions. However, funding opportunities
are sparse, and resources are reluctantly applied to pre-
vention, let alone early life factors that are decades
removed from cancer occurrence. We hope our pressing
call to action will be heard.
Diet after a diagnosis of cancer
Rebecca J. Beeken (Fig. 11) and Edward L. Giovannucci
(Fig. 6)
There is increasing evidence that, in addition to playing a
role in cancer development, diet may influence outcomes
after cancer diagnosis [71]. However, the current recom-
mendations for survivors are based largely on extrapolation
from cancer prevention recommendations. Dietary sur-
vivorship studies encompass a variety of settings, including
general nutritional support for advanced stage cancer pa-
tients, specific dietary factors or nutrients that may im-
prove treatment responses and survival for specific
cancers, and the influence of nutrition for overall mortality
with cancers that have a good prognosis for long-term sur-
vival and for which the main causes of death will not be re-
lated to the cancer itself; the issues for each of these vary.
There is an urgent need for carefully designed and ad-
equately powered cohort studies and randomized interven-
tions with appropriate outcomes for each phase of survival
across cancer types. While large scale interventions may
ultimately provide the strongest evidence, rigorous assess-
ment of observational data is essential to justify them.
Beyond the typical challenges of observational studies of
diet and nutrition and cancer incidence, survivorship
studies have additional challenges. First, any effects could
differ by cancer stage, cancer subtypes, and by treatment,
which could all influence survival. Thus, the recommen-
dations for survivorship may need to be more nuanced
than those for primary prevention. Careful consideration
needs to be given to how best to communicate these com-
plex, and potentially changing, messages to healthcare
professionals, patients, and the public. Secondly, because
the study population already has cancer, the potential for
reverse causation for observed associations is substantial.
For example, higher levels of physical activity post-
diagnosis appear to be associated with better survival for
some cancers, but a possibility may be that patients who
become progressively sicker, and hence have a poorer
prognosis, may be less able to exercise. Finally, behaviors
in the post-diagnostic period may correlate with those in
the pre-diagnostic period, so if an association is observed
in the post-diagnostic period, the causal effect could be
occurring in the pre-diagnostic period. Thus, an interven-
tion based on such observations, if begun in the post-
diagnostic phase, may not confer the benefit suggested in
the observational study. Studies combining primary pre-
vention with post-diagnostic work may offer unique op-
portunities to explore the impact of interventions across
the cancer continuum.
There are also practical challenges for studies that are
specific to the post-diagnosis setting. In particular, the
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support of healthcare professionals is crucial for recruit-
ment of patients and implementation of any successful
intervention. Healthcare professionals can act as gate-
keepers, limiting patient access to interventions and
biasing recruited samples. The challenge of engaging cli-
nicians who face a number of competing time demands
and have concerns around the effectiveness of an inter-
vention, as well as patient blaming, their perceived lack
of interest, and them being too ill to participate, needs
to be addressed [72, 73]. Strategies are needed that ad-
dress the range of barriers to participation in, and adher-
ence to, interventions among people with a diagnosis of
cancer, especially hard-to-reach patients [74–76], to en-
sure existing inequalities in outcomes are not increased.
Additionally, there is a need to better understand mech-
anisms of action of interventions and to untangle the
complex interplay of nutrition, physical activity, and
weight on any observed effects; it is inadequate to study
nutritional factors in isolation. Furthermore, developing
interventions that not only change behavior but also sup-
port individuals to maintain those changes over the longer
term represents a significant challenge [77]. Theories that
specifically address maintenance, such as habit-formation
theory [78], may offer useful starting points, but have not
been widely tested [79]. Research to identify the optimal
triangulation of dose, modality and timing of interven-
tions, and the extent to which interventions can and
should be personalized is also needed. Digital technologies
and the use of artificial intelligence may offer new, more
efficient means of tailoring interventions.
To date, dietary intervention studies have predomin-
antly focused on survivors of common cancers (breast,
colorectal, and prostate) who have completed treatment.
However, there is increasing interest in developing inter-
ventions for delivery during the post-diagnosis but pre-
treatment stage (i.e., prehab) [80], and for patients facing
recurrence or with incurable disease [81]. The feasibility
of integrating such interventions into standard care needs
to be examined and identifying appropriate outcome mea-
sures is crucial. Studies assessing the effect of interven-
tions on patient-reported outcomes, quality of life, and
symptom management, as pre-planned, primary endpoints
are lacking [82]. Recent studies have begun to explore po-
tential interactions between nutrition and treatment [45]
and the role of the microbiome and immune system via
biomarker trials [83, 84]. Results from ongoing trials ex-
ploring the impact of behavioral interventions on cancer-
relevant outcomes are also eagerly awaited, but these re-
quire substantial efforts. There is also a call to make better
use of existing data and to promote the collection of nutri-
tion data from patients as part of standard care to support
this endeavor going forward.
The food environment and cancer prevention
Linda Bauld (Fig. 12) and Hilary J. Powers (Fig. 13)
Considerable progress has been made in understanding
the causal links between diet, nutrition, physical activity,
weight, and cancer incidence. Research findings have in-
formed guidance on cancer prevention from national
and international organizations [7, 85]. These guidelines
commonly provide information on healthier diets, main-
taining a healthy weight, avoiding sedentary behavior,
engaging in physical activity, and avoiding alcohol. There
is good evidence that adhering to cancer prevention rec-
ommendations is associated with lower risk of some
cancers [86, 87]. However, there are well-acknowledged
obstacles that individuals and communities face in ad-
hering to cancer prevention recommendations and at-
tention needs to be focused on addressing the wider
social and commercial determinants that affect individ-
ual capability, opportunity, and motivation to engage in
healthy behaviors [88, 89]. In particular, inadequate at-
tention has been paid to food environments, notably the
pricing, promotion, and availability of different types of
food and the content, formulation, packaging, and label-
ling of products [90]. Also described as the ‘foodscape’
[91], food environments include the physical environ-
ment, which is particularly relevant when considering
overweight and obesity as a risk factor for cancer.
The consumption of high energy and low nutrient
processed foods is a strong and prevalent risk factor for
Fig. 11 Rebecca J Beeken, PhD, is a tenure-track Yorkshire Cancer
Research University Academic Fellow at the University of Leeds. Her
academic background is in behavioral science and health psychology,
and her primary research interest is in behavior change for cancer
prevention and control. Rebecca currently co-leads a Cancer Research
UK-funded program of work exploring the efficacy of a brief, habit-
based intervention for improving dietary and physical activity behaviors
in people living with a diagnosis of cancer
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overweight and obesity and reducing the intake of these
products is relevant for cancer prevention [92]. There is
growing evidence that marketing and promotion affects
dietary choices, including among children; exposure to
high energy and low nutrient processed food advertise-
ments on television and increasingly online has been
shown to increase energy intake [93, 94]. The availability
of these types of foods also has a role to play. For ex-
ample, studies have identified a positive association be-
tween the density of unhealthy food outlets in a
neighborhood and the prevalence of overweight and
obesity in children [95, 96]. Location of high energy food
items by tills in retail outlets can also influence choice
[97, 98]. The relationship between deprivation and poor
diet also calls for a greater focus on the food environ-
ment. Studies in a number of high-income countries,
including the UK, have found that there is a clustering
of fast food outlets in areas of deprivation along with
more limited access to retail outlets that provide a wider
range of healthier food options [99, 100].
Changing the food environment is possible and doing
so could make an important contribution to the preven-
tion of cancers linked to dietary risk factors and over-
weight and obesity. Action by retailers and
manufacturers can contribute, as recently demonstrated
by some success in voluntary reformulation to reduce
salt in a range of products, and in the removal of confec-
tionary from supermarket checkout aisles [98]. Arguably,
however, population level policies introduced by govern-
ments have the greatest role to play. There is promising
evidence that fiscal policies, including taxes on sugar-
sweetened beverages, can reduce consumption of these
products [101, 102]. Restrictions on marketing, including
the timing, content, and extent of advertising, could
affect consumption, particularly by children, and help
shift social norms away from prevalent dietary choices
that favor high energy and low nutrient processed foods.
Greater attention should also be given to the local policy
context and the importance of spatial planning for
health. Local planning tools should be used to limit the
growth and proliferation of unhealthy food outlets [103].
Planning decisions should also give greater consideration
to the provision of opportunities for increased physical
Fig. 13 Hilary Powers is Professor Emerita at the University of
Sheffield, UK. Her research has focused on micronutrients and cancer
risk, at the epidemiology and molecular level. She has worked
extensively with World Cancer Research Fund International on their
reports into food, nutrition, physical activity, and cancer prevention
Fig. 12 Linda Bauld is the Bruce and John Usher Professor of Public
Health at the University of Edinburgh, Deputy Director of the UK
Centre for Tobacco and Alcohol Studies, and holds the CRUK/BUPA
Chair in Cancer Prevention at Cancer Research UK. She is a behavioral
scientist with a particular interest in the primary prevention of cancer
and has conducted a range of studies to inform or evaluate policies
and programs to address tobacco, alcohol, and overweight and
obesity. She is a former scientific adviser on tobacco control to the UK
government and is a member of a number of policy and research
funding committees in the UK, Canada, and Europe
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activity. There is evidence from different countries that
planning decisions that provide useable green spaces in
urban settings, a better cycling and walking infrastruc-
ture, and accessible public transport options can be ef-
fective in increasing physical activity [104].
Research to inform the development of policies and
interventions to improve the food environment and
prioritize cancer and other noncommunicable disease
prevention efforts requires interdisciplinary collabora-
tions between researchers with skills in nutrition, be-
havioral science, economics, geography, epidemiology,
and other disciplines. Researchers need skills, not only
in identifying appropriate context-specific methods
and analysis, but also in knowledge translation and in
engaging policymakers and the public. Support to
identify appropriate frameworks and circumstances
for collaboration with industry are also required,
along with skills to understand and address conflicts
of interest, both in the conduct of research and the
availability and interpretation of often conflicting
sources of evidence [105, 106]. Food systems and the
food environment are complex and adaptive and re-
search to better understand and improve them should
to be similarly responsive [107].
Conclusions
Jessica Brand (Fig. 14) and Rachel A. Reinhardt (Fig. 15)
Ludwig Cancer Research and Cancer Research UK are
privileged to have brought together world leaders in the
field for a holistic discussion of the current challenges
and opportunities in nutrition and cancer prevention. As
discussed in this Forum article, strong themes emerged
from the conference, consistently highlighting that obes-
ity prevention, nutrition, and physical activity play a
major role in worldwide cancer prevention. Many factors
impact on progress with respect to these themes, which
will be best served through integrated and systematic re-
search. These include, for example, different experiences
in childhood and the physical, social, economic, and
digital environments that we inhabit.
Fig. 14 Jessica Brand is a Research Funding Manager in the
Population, Prevention and Behavioural Research team at Cancer
Research UK (CRUK) with a specific focus on the prevention elements
of the portfolio. Having completed a BSc in Chemistry, she worked in
academic journal publishing at the Royal Society of Chemistry, before
moving onto project managing small researcher support grant
schemes. Other roles in grant management followed, and she has
been with CRUK since August 2017
Fig. 15 Rachel Reinhardt is the Vice President for Communications
at the Ludwig Institute for Cancer Research. Prior to that, she held
communications leadership positions at the Juvenile Diabetes
Research Foundation, the International AIDS Vaccine Initiative, and
France Telecom North America. Rachel is a graduate of Yale University
with a dual degree in French and International Studies
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We thank all the contributors to this Forum article for
their thoughtful and significant input, and for helping to
drive a meaningful discussion.
We look forward to catalyzing additional interdiscip-
linary discussions in cancer prevention. Such dialogue
will hopefully help identify opportunities to further in-
vigorate research activities towards understanding the
interrelationships of obesity, nutrition, and physical ac-
tivity in cancer prevention, and how this knowledge
might best be utilized to advance public health.
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